Join the Lamivudine group to help and get support from people like you.
Lamivudine News
Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
TUESDAY, May 20, 2025 – Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a significantly lower...
Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...
Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...
FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection
February 6, 2015 – The United States Food and Drug Administration (FDA) has approved Dutrebis, a fixed dose combination tablet containing 150 mg of lamivudine and 300 mg of raltegravir. Dutrebis...
FDA Approves Triumeq for the Treatment of HIV-1 Infection
August 22, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...